Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio

Key Takeaways

• Lilly pays $75M upfront, up to $1.185B milestones for sonefpeglutide.
• Servier's Edgewise deal totals up to $2.65B for sevasemten program.
• Avenzo-Rallybio merger secures $215M financing, targeting CDK inhibitors and ADCs.
• Sevasemten is in pivotal Becker trial and Phase II Duchenne study.
• Avenzo shareholders will own about 97.2% of the combined public company.

Pulse Analysis

Big‑pharma licensing remains a fast‑track to diversify pipelines, and Eli Lilly’s agreement with Hanmi exemplifies that model. By securing worldwide rights to sonefpeglutide—a long‑acting GLP‑2 analog—Lilly taps into a niche yet sizable market for short‑bowel syndrome and related gastrointestinal disorders. The $75 million upfront payment, coupled with potential $1.185 billion in milestones, reflects confidence in Hanmi’s Lapscovery platform, which already supports an FDA‑approved biologic and several late‑stage candidates. This deal also positions Lilly to leverage its global commercialization expertise while Hanmi retains development control in Korea.

In neuromuscular therapeutics, Servier’s acquisition of Edgewise’s muscular‑dystrophy assets marks one of the largest rare‑disease deals this year. The transaction, valued at up to $2.65 billion, adds sevasemten—a first‑in‑class oral fast skeletal myosin inhibitor—to Servier’s Servier 2030 neurology strategy. With pivotal data emerging in Becker muscular dystrophy and a Phase II study in Duchenne, the asset addresses a critical unmet need where no approved therapies exist. Servier gains not only the drug candidate but also Edgewise’s development team and manufacturing know‑how, accelerating its push into a market projected to grow as gene‑editing and exon‑skipping technologies mature.

Avenzo Therapeutics’ merger with Rallybio illustrates how biotech firms are using SPAC‑like structures to secure growth capital. The $215 million private placement, oversubscribed by investors, funds four oncology programs, including selective CDK2/4 inhibitors for breast cancer and bispecific antibody‑drug conjugates targeting solid tumors. By consolidating under the AVZO ticker, Avenzo gains public‑market visibility while retaining 97.2% ownership for existing shareholders. This approach reflects a broader trend where mid‑stage companies favor merger‑driven listings to bypass the lengthy IPO process, ensuring sufficient runway to advance late‑stage trials and attract strategic partners.